362 related articles for article (PubMed ID: 22213157)
21. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
22. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
Campbell J; Mohiuddin SM
Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712
[TBL] [Abstract][Full Text] [Related]
23. The role of fenofibrate in clinical practice.
Zambon A; Cusi K
Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
[TBL] [Abstract][Full Text] [Related]
24. A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Steiner G
Treat Endocrinol; 2005; 4(5):311-7. PubMed ID: 16185099
[TBL] [Abstract][Full Text] [Related]
25. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
26. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.
Matikainen N; Taskinen MR
Curr Cardiol Rep; 2012 Dec; 14(6):721-31. PubMed ID: 22941588
[TBL] [Abstract][Full Text] [Related]
27. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis.
Choi HD; Shin WG; Lee JY; Kang BC
Vascul Pharmacol; 2015; 65-66():23-30. PubMed ID: 25451563
[TBL] [Abstract][Full Text] [Related]
29. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
30. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
31. Fibrates after the FIELD study: Some answers, more questions.
Wierzbicki AS
Diab Vasc Dis Res; 2006 Dec; 3(3):166-71. PubMed ID: 17160911
[TBL] [Abstract][Full Text] [Related]
32. Do persons with stroke benefit from statin-fibrate combination therapy?
Castilla-Guerra L; Fernandez-Moreno Mdel C
Eur J Intern Med; 2015 Mar; 26(2):148-9. PubMed ID: 25620642
[No Abstract] [Full Text] [Related]
33. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.
Watts GF; Karpe F
Heart; 2011 Mar; 97(5):350-6. PubMed ID: 21296781
[TBL] [Abstract][Full Text] [Related]
34. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
35. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
[TBL] [Abstract][Full Text] [Related]
36. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
[TBL] [Abstract][Full Text] [Related]
37. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins.
Anabtawi A; Moriarty PM; Miles JM
Curr Cardiol Rep; 2017 Jul; 19(7):62. PubMed ID: 28528456
[TBL] [Abstract][Full Text] [Related]
39. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
40. Physician variation in the de-adoption of ineffective statin and fibrate therapy.
Everhart A; Desai NR; Dowd B; Herrin J; Higuera L; Jeffery MM; Jena AB; Ross JS; Shah ND; Smith LB; Karaca-Mandic P
Health Serv Res; 2021 Oct; 56(5):919-931. PubMed ID: 33569804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]